Clarifying the Optimal Application of SLT Therapy Trial

Inclusion Criteria:

1. Age 18 or older and in good health

2. Each eye with one of the following qualifying diagnoses (diagnoses may differbetween eyes):

3. High-risk ocular hypertension (OHT): IOP > 21 mmHg without glaucomatous opticneuropathy (excavation, diffuse or focal thinning or notching of theneuroretinal rim, visible nerve fiber layer defects, or asymmetry of thevertical cup-to-disc ratio of >0.2 between eyes)

4. Mild primary open-angle glaucoma: glaucomatous optic neuropathy, visual fieldmean deviation better than -6.0 dB with no points in the central 5° <15 dB (seefigure on next page)

5. Moderate primary open-angle glaucoma: glaucomatous optic neuropathy, visualfield mean deviation equal to or worse than -6.0 dB but no worse than -12.0 dBand no central 5° points <15 dB or mean deviation -12.0 dB or better with 1central 5° points <15 dB (see figure on next page).

6. Each eye with BCVA 20/200 (UK 6/60) or better

Exclusion Criteria:

1. Use of topical IOP-lowering medications for more than 6 cumulative months at anytime in the past 5 years (this is a modification implemented during activeenrollment)

2. Any history of IOP-lowering laser (prophylactic iridotomy not included) or surgicalprocedure

3. Advanced POAG in either eye (worse than moderate POAG as defined above)

4. Glaucoma other than POAG (including pigmentary and pseudoexfoliation glaucoma) ineither eye

5. Mean IOP > 35 mmHg at either the screening or baseline visit in either eye

6. Narrow or closed angle (Shaffer Grade 0, 1, or 2) in either eye

7. Contraindications to SLT or any other study intervention

8. Any corneal pathology that would preclude accurate assessment of IOP by Goldmanntonometry in either eye

9. Any intraocular surgical procedure within the past 6 months in either eye

10. Inability to attend all scheduled study visits

11. Pregnant or planning to become pregnant in the next 4 years